Prognostic value of circulating CD34+ cells in myelodysplastic syndromes

✍ Scribed by Clara Cesana; Catherine Klersy; Bruno Brando; Annamaria Nosari; Barbara Scarpati; Linda Scampini; Alfredo Molteni; Guido Nador; Luca Santoleri; Marta Formenti; Marina Valentini; Antonino Mazzone; Enrica Morra; Roberto Cairoli

• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 384 KB
• Volume: 32
• Category: Article
• ISSN: 0145-2126
• DOI: 10.1016/j.leukres.2008.03.028

✦ Synopsis

We studied circulating (C)CD34 + cells by flow cytometry in 96 patients with myelodisplastic syndromes (MDS) at diagnosis, and in a subset of 35 cases during follow-up. CCD34 + counts were stratified within both International Prognostic Scoring System (IPSS) and World Health Organization (WHO) categories. Counts >10/l were associated with poorer leukemia-free survival, a prognostic value for evolution independent from that of WHO, and a higher progression probability within intermediate-risk IPSS and WHO classes. When serial measurements were performed, counts >10/l more frequently correlated to evolution. Separating newly diagnosed patients on the basis of 10/l cut-off of circulating CD34 + cells retains prognostic utility, especially in intermediate-risk MDS.